Description

Founded in 2003 and headquartered in Sheung Wan, Hong Kong, Guangdong Hybribio Biotech Co.,Ltd. specializes in the research, development, and commercialization of nucleic acid-based molecular diagnostic solutions. The company caters to hospitals and medical facilities, providing a comprehensive range of in-vitro diagnostic (IVD) kits. These kits target various health concerns, including human papillomavirus (HPV), sexually transmitted infections (STIs), thalassemia, and conditions requiring prenatal or postnatal screening. Their product portfolio extends to specific real-time PCR kits for STIs, Hepatitis B virus, and COVID-19, alongside genoarray diagnostic kits for thalassemia and hereditary hearing loss susceptibility. In addition to diagnostic reagents, Hybribio manufactures and supplies advanced laboratory instruments, such as automated systems for nucleic acid extraction, medical PCR analysis, flow-through hybridization, and fluorescent quantitative detection. They also offer robust after-sales technical support. Hybribio's offerings are integral to national health screening initiatives, clinical diagnostics, and research efforts, reaching markets across the Asia Pacific, Southeast Asia, the Middle East, Europe, Africa, and South America.